EMA Authorised: Nepexto (etanercept) — Biosimilar Collaborations Ireland Limited

View source ↗

Summary

EMA authorised Nepexto, a biosimilar of etanercept, developed by Biosimilar Collaborations Ireland Limited, for several inflammatory arthritis conditions includ…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ankylosing Spondylitis
• Juvenile Idiopathic Arthritis
• Psoriasis
• Psoriatic Arthritis
• Rheumatoid Arthritis
• Spondyloarthropathies

Drugs mentioned

• Nepexto (etanercept)

Snippet

Status: Authorised. Therapeutic area: Arthritis, Rheumatoid;Arthritis, Juvenile Rheumatoid;Arthritis, Psoriatic;Spondylarthropathies;Spondylitis, Ankylosing;Psoriasis. MAH: Biosimilar Collaborations Ireland Limited. Decision date: 12/02/2025